Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Tue Nov 14 00:00:00 GMT-04:00 2017
Data at SABCS and ASH Demonstrate Daiichi Sankyo Commitment to Advancing Science in Breast and Bloo ...
PDF (195 KB)
Wed Nov 08 00:00:00 GMT-04:00 2017
Daiichi Sankyo, Inc., Announces New Analyses of Once-Daily SAVAYSA® (edoxaban) to be Presented at t ...
PDF (214 KB)
Fri Nov 03 00:00:00 GMT-04:00 2017
Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce U.S. Availability of MorphaBond™ ...
PDF (289 KB)
Tue Oct 31 00:00:00 GMT-04:00 2017
Daiichi Sankyo Announces ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in Tenosynovial ...
PDF (152 KB)
Mon Oct 30 00:00:00 GMT-04:00 2017
Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collab ...
PDF (239 KB)
Wed Oct 04 00:00:00 GMT-04:00 2017
Daiichi Sankyo, Inc. Announces Commitments in Pain Care Program
PDF (330 KB)
Thu Sep 14 00:00:00 GMT-04:00 2017
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myel ...
PDF (260 KB)
Mon Sep 11 00:00:00 GMT-04:00 2017
Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European S ...
PDF (213 KB)
Wed Sep 06 00:00:00 GMT-04:00 2017
Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinica ...
PDF (306 KB)
Thu Aug 31 00:00:00 GMT-04:00 2017
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabal ...
PDF (98 KB)
Showing 1 - 10 of 39 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...